Rhinology最新文献

Age-related exacerbation in disease-associated olfactory disorders. 疾病相关嗅觉障碍的年龄相关性恶化。

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-17 DOI: 10.4193/Rhin24.227

H Shimmura, E Mori, R Sekine, M Tei, N Otori

{"title":"Age-related exacerbation in disease-associated olfactory disorders.","authors":"H Shimmura, E Mori, R Sekine, M Tei, N Otori","doi":"10.4193/Rhin24.227","DOIUrl":"https://doi.org/10.4193/Rhin24.227","url":null,"abstract":"Background: Both the physiological degeneration linked to aging and the pathological changes resulting from diseases can impact olfactory function in the patients with olfactory disorder (OD). However, the epidemiological literature addressing the extent of aging's involvement to the diseases which causes OD is limited. Our study aimed to investigate how aging affects olfactory function in major causes of OD by employing psychophysical olfactory sensory testing.Methodology: Non-eosinophilic chronic rhinosinusitis (NECRS), eosinophilic chronic rhinosinusitis (ECRS), post-infectious OD (PIOD), post-traumatic OD, and idiopathic OD were identified as major contributors to OD. Retrospective data from 1986 patients were collected from our smell clinic. We utilized T&T olfactometer thresholds to assess quantitative olfactory function. Patients were categorized into age groups spanning every 10 years from their 20s to 80s, and we analyzed potential differences between age groups and diseases. Additionally, the odds ratio of severe OD was analyzed with respect to gender and age, categorizing patients into two groups: lower than 60 and over or equal to 60.Results: A significant odds ratio was observed for elevated T&T average threshold with respect to age in the detection and recognition thresholds of patients diagnosed with NECRS, PIOD and idiopathic OD. In contrast, no significant odds ratio was observed in patients with ECRS or post-traumatic OD, regardless of age.Conclusion: Analysis of disease-specific OD revealed varying degrees of age-related physiological and disease-pathological across different conditions. These findings underscore the importance for clinicians to consider both age-related physiological changes and the specific disease pathology of the disease when diagnosing and managing OD, particularly in elderly patients.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidimensional benefits of olfactory training for chronic COVID-19-related olfactory dysfunction: a systematic review and meta-analysis. 嗅觉训练对慢性covid -19相关嗅觉功能障碍的多维益处：系统综述和荟萃分析

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-04 DOI: 10.4193/Rhin24.355

C-H Chen, C-F Shih, T Hummel, Y-T Chao

{"title":"Multidimensional benefits of olfactory training for chronic COVID-19-related olfactory dysfunction: a systematic review and meta-analysis.","authors":"C-H Chen, C-F Shih, T Hummel, Y-T Chao","doi":"10.4193/Rhin24.355","DOIUrl":"https://doi.org/10.4193/Rhin24.355","url":null,"abstract":"Background: Olfactory dysfunction is commonly observed in patients with COVID-19 infection. Chronic olfactory dysfunction can have a profound effect on one's quality of life. Olfactory training (OT) is a rehabilitation therapy, which has emerged as a viable treatment for COVID-19-related olfactory dysfunction. Our primary objective was to assess the effectiveness of OT for individuals with chronic COVID-19-related olfactory dysfunction.Methods: A search was performed on the Cochrane Library, Embase, PubMed, Scopus, and Web of Science databases from their inception through Feb 24, 2024. Eligible studies included those with sufficient information for meta-analysis pertaining to the effectiveness of OT performed for more than 8 weeks in treating chronic (duration > 16 weeks) COVID-19-related olfactory dysfunction.Results: After a systematic review of all relevant articles, 9 studies qualified for inclusion. A total of 179 patients within 7 studies had eligible Sniffin' Sticks test data. The pooled results showed significant post-OT increases in TDI score, threshold, discrimination, and identification. Two studies documented qualified UPSIT scores in 63 patients. Pooled results of all identification tests revealed significant improvement.Conclusions: OT demonstrates benefits in treating chronic COVID-19-related olfactory dysfunction, as evidenced by multidimensional evaluations. These findings suggest the involvement of both top-down and bottom-up mechanisms in the recovery process.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and recovery rate of persistent olfactory dysfunction in COVID-19: the COVORTS study. COVID-19患者持续性嗅觉功能障碍的患病率和恢复率：COVORTS研究

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.331

B van Dijk, E M Postma, W M Boek, D M A Kamalski, S Boesveldt

{"title":"Prevalence and recovery rate of persistent olfactory dysfunction in COVID-19: the COVORTS study.","authors":"B van Dijk, E M Postma, W M Boek, D M A Kamalski, S Boesveldt","doi":"10.4193/Rhin24.331","DOIUrl":"10.4193/Rhin24.331","url":null,"abstract":"Background: Olfactory dysfunction is a well-recognized symptom of COVID-19 infection. However, prevalence and recovery rate of these persistent symptoms differ across reports. Here, we report prevalence and recovery rate of psychophysically measured quantitative olfactory dysfunction, qualitative complaints, and subjective olfactory functioning up to 15 months after infection.Methodology: The COVORTS cohort included 76 patients between 18-60 years with recent (1 month) olfactory dysfunction. The (extended) Sniffinâ€™ Sticks test was performed at baseline (T1), and 3 months, 6 months, 9 months, and 12 months later (T13). Monthly online questionnaires were completed on self-reported overall olfactory functioning and qualitative complaints.Results: Prevalence of quantitative olfactory dysfunction was 89.5% at baseline, and 69.1% at T13. Clinically relevant recovery was achieved by 29.4% of patients at T13. Prevalence of parosmia remained around 50%, while phantosmia slowly decreased from 43.4% to 23.5%. Subjective olfactory functioning slowly improved over time before levelling out at around half of pre-illness ability. At T13, 37.9% of patients reported an improvement of at least 80% of pre-COVID function. Fluctuations were observed within individuals for all three measurements.Conclusions: Irrespective of measurement method, prevalence of olfactory dysfunction remains high up to 15 months after infection, and recovery rate is low. Individual fluctuations were observed between timepoints, indicating that recovery is not stable. Acknowledgement of symptoms, knowledge of fluctuations, and longer follow-up to evaluate further recovery are crucial to improve patient management.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"334-342"},"PeriodicalIF":4.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mepolizumab in severe uncontrolled CRSwNP: a real-life multicentre study in Northeast Italy. Mepolizumab治疗严重不受控制的CRSwNP：意大利东北部一项真实的多中心研究

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.420

G Ottaviano, G Roccuzzo, T Saccardo, L G Locatello, S De Rossi, A De Massimi, E Rigoni, R Marangoni, L Lora, L Calvanese, M Schiappoli, L Pierotello, S Munari, M Baldovin, F Corliano, I Barbarino, S Santini, S Zampollo, K Pacaj, B Scarpa, P Nicolai

{"title":"Mepolizumab in severe uncontrolled CRSwNP: a real-life multicentre study in Northeast Italy.","authors":"G Ottaviano, G Roccuzzo, T Saccardo, L G Locatello, S De Rossi, A De Massimi, E Rigoni, R Marangoni, L Lora, L Calvanese, M Schiappoli, L Pierotello, S Munari, M Baldovin, F Corliano, I Barbarino, S Santini, S Zampollo, K Pacaj, B Scarpa, P Nicolai","doi":"10.4193/Rhin24.420","DOIUrl":"10.4193/Rhin24.420","url":null,"abstract":"Background: The aim of this study was to evaluate the efficacy of mepolizumab as add-on therapy to intranasal corticosteroids for the treatment of severe, uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in a real-life setting in the Triveneto region of northeast Italy.Methods: Patients with severe CRSwNP receiving mepolizumab were followed up at 1, 3, 6, 9 and 12 months from the first administration. At baseline and at each follow-up, patients underwent nasal endoscopy, completed the Sinonasal Outcome Test 22, Visual Analogue Scales for smell, nasal obstruction, rhinorrhoea and facial pain, the Nasal Congestion Score and the Asthma Control Test. Peak nasal inspiratory flow, Sniffinâ€™ Sticks Identification Test and blood eosinophil count were also evaluated.Results: Ninety patients from twelve different rhinological units were enrolled in the study. Both patient- and physician- derived outcome measures significantly improved within the first month after biological treatment initiation, maintaining the benefit at subsequent follow-ups. Nine percent of patients discontinued the treatment due to lack of benefit within the first year. No major adverse events were reported.Conclusions: Mepolizumab is effective in improving nasal obstruction and the sense of smell in patients with severe uncontrolled CRSwNP, based on both patient- and physician derived outcome measures.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"343-352"},"PeriodicalIF":4.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating pretreatment 18F-FDG PET-CT parameters, peripheral blood indicators and clinical characteristics in predicting chemotherapy plus immunotherapy outcomes for de novo metastatic nasopharyngeal carcinoma. 整合预处理18F-FDG PET-CT参数、外周血指标及临床特征预测新转移性鼻咽癌化疗加免疫治疗结果

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.547

L-W Gu, Y-C Li, S-Y Xue, B-B Xiao, D-X Wen, L-P Wu, X Zhang, L-Q Tang, L Guo, L-T Liu

{"title":"Integrating pretreatment 18F-FDG PET-CT parameters, peripheral blood indicators and clinical characteristics in predicting chemotherapy plus immunotherapy outcomes for de novo metastatic nasopharyngeal carcinoma.","authors":"L-W Gu, Y-C Li, S-Y Xue, B-B Xiao, D-X Wen, L-P Wu, X Zhang, L-Q Tang, L Guo, L-T Liu","doi":"10.4193/Rhin24.547","DOIUrl":"10.4193/Rhin24.547","url":null,"abstract":"Background: To develop a prognostic nomogram based on pretreatment 18F-FDG PET-CT radiomics parameters, peripheral blood indicators and clinical characteristics for risk stratification in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving immunochemotherapy.Methodology: The eligible patients were randomly divided into training (n=183) and validation (n=79) cohorts. Least absolute shrinkage and selection operator regression was used for variable selection. Multivariate Cox regression analysis was performed to identify independent prognostic factors for progression-free survival (PFS). The predictive accuracy and discriminative ability of the nomogram were determined with a concordance index (C-index) and calibration curve.Results: Multivariate Cox analysis suggested that total lesion glycolysis, number of metastases, Epsteinâ€\"Barr virus DNA, N-stage, lactate dehydrogenase, and total bilirubin were independent predictors of PFS and were used to develop a nomogram that could classify patients into low- and high-risk groups. The C-index of the nomogram for predicting disease progression was 0.75, which was significantly higher than the C-indices of the TNM stage and EBV DNA. The patients were then stratified into low- and high-risk groups based on the calculated scores. The median PFS was significantly higher in the low-risk group than in the high-risk group.Conclusions: The proposed nomogram with PET-CT parameters, peripheral blood indicators and clinical characteristics resulted in accurate prognostic prediction for patients with dmNPC receiving chemotherapy plus PD-1 inhibitors and could provide risk stratification for these patients.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"363-372"},"PeriodicalIF":4.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Caudal septoplasty, a literature review. 尾隔成形术，文献综述。

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.415

A Javed, A Alburaiki, A Kamber Zaidi, M U Farooq, J Limbrick, S Anari

{"title":"Caudal septoplasty, a literature review.","authors":"A Javed, A Alburaiki, A Kamber Zaidi, M U Farooq, J Limbrick, S Anari","doi":"10.4193/Rhin24.415","DOIUrl":"10.4193/Rhin24.415","url":null,"abstract":"Background: Caudal septal deviation accounts for around five percent of patients with septal deviations that require surgery. The caudal septum provides support to the nasal tip and the deviations can narrow the nasal airway and lead to marked asymmetry in nostril shape. Over-resection of this area can compromise the structural support leading to tip collapse or saddle nose deformity. This necessitates alternative techniques to submucosal resection for surgical correction of caudal septal deviations.Methodology: This study provides a review of different surgical techniques, including open and closed septoplasty in the literature to address caudal septal deviation. Each technique is described along with a surgical illustration, its advantages, limitations, and examples of case studies with surgical outcomes.Results: The submucosal resection is a commonly used method but can only be used if the septal deviation is not involving the L-strut. Other methods include scoring, swinging door, doorstop, and suturing techniques either as a stand-alone or used combined with cutting techniques. Batten graft can be used alone or in conjunction with the other methods. Extracorporeal septoplasty is used in cases of severe deformity.Conclusions: There is a variety of methods to address caudal septal deviation. Correcting the caudal septal deviation requires proper pre-operative planning and accurate execution of surgical techniques. More research on surgical outcomes is needed to improve the evidence base.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"306-315"},"PeriodicalIF":4.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study. 比利时未控制的严重慢性鼻窦炎伴鼻息肉的生物治疗效果：一项多中心真实世界数据研究。

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.509

A-S Viskens, L Bollens, E Borgers, S Halewyck, V Hox, M Jorissen, W Lemmens, F Rogister, K Speleman, L Van Gerven, O Vanderveken, B Verhaeghe, A Vroegop, K Martens, P W Hellings

{"title":"Effect of biological treatment in uncontrolled severe chronic rhinosinusitis with nasal polyps in Belgium: a multicentre real-world data study.","authors":"A-S Viskens, L Bollens, E Borgers, S Halewyck, V Hox, M Jorissen, W Lemmens, F Rogister, K Speleman, L Van Gerven, O Vanderveken, B Verhaeghe, A Vroegop, K Martens, P W Hellings","doi":"10.4193/Rhin24.509","DOIUrl":"10.4193/Rhin24.509","url":null,"abstract":"Background: Double-blinded placebo-controlled trials have revealed the efficacy of mepolizumab and omalizumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). However, real-world efficacy (RWE) data, data on therapeutic response and level of disease control for both biologicals are lacking.Methodology: 167 patients with uncontrolled severe CRSwNP, meeting national reimbursement criteria, were included with follow-up over 24 weeks. Primary outcomes included changes in nasal congestion (NCS), nasal polyp score (NPS), VAS-scores, SNOT-22, ACQ-5, and AQLQ scores. Secondary outcomes were therapeutic response and disease control according to EUFOREA/EPOS criteria.Results: Of the 167 CRSwNP patients, 144 received mepolizumab and 23 omalizumab. After 24 weeks, Patient reported outcomes and NPS significantly improved for both biologicals, with significant effects seen at 12 weeks, with further reduction in NPS by 24 weeks in mepolizumab patients. 74% of patients on omalizumab and 81% of patients on mepolizumab continued their therapy beyond 24 weeks, with 47% and 45% of patients on omalizumab and mepolizumab respectively showing an excellent therapeutic response, with only one out of seven having no/poor response. Disease control was reached in one third of the patients at 24 weeks.Conclusions: Both mepolizumab and omalizumab significantly improved patient-reported outcomes after 24-weeks, with major effects already observed at 12 weeks. Follow-up beyond 24-weeks might reveal additional effects on both control and remission.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"316-324"},"PeriodicalIF":4.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mouse model of Staphylococcus aureus- and Pseudomonas aeruginosa-induced neutrophilic chronic rhinosinusitis. 金黄色葡萄球菌和铜绿假单胞菌诱导的嗜中性粒细胞慢性鼻窦炎小鼠模型。

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.545

A Sanchez-Montalvo, A Ziani-Zeryouh, M Lecocq, B Steelant, S Gohy, P Hellings, D Bullens, C Pilette, V Hox

{"title":"Mouse model of Staphylococcus aureus- and Pseudomonas aeruginosa-induced neutrophilic chronic rhinosinusitis.","authors":"A Sanchez-Montalvo, A Ziani-Zeryouh, M Lecocq, B Steelant, S Gohy, P Hellings, D Bullens, C Pilette, V Hox","doi":"10.4193/Rhin24.545","DOIUrl":"10.4193/Rhin24.545","url":null,"abstract":"Background: Chronic rhinosinusitis (CRS) is a highly prevalent upper airway disease. Its pathogenesis remains poorly understood, especially non-eosinophilic CRS. Currently, no validated mouse model exists to study disease mechanisms, indicating an important research gap. We aimed at establishing a reproducible mouse model of non-eosinophilic CRS to allow further research on its pathophysiology.Methodology: Mice were infected with relevant bacteria for sinus disease via surgical insertion of a nasal tampon in their nasal cavity. Inflammatory features in sinus mucosa were evaluated after 4, 8 and 12 weeks on decalcified skulls by histology and immunohistochemistry and by cytospins and enzyme-linked immunoassay on nasal lavage.Results: S. aureus-inoculated mice showed better survival than S. pneumoniae- and P. aeruginosa- inoculated mice. S. aureus and, to lesser extent, P. aeruginosa were still detectable in the nasal lavage up to 12 weeks. Mice with S. aureus and P. aeruginosa-induced CRS showed significant hypertrophia of the epithelium, neutrophilic infiltration and fibrosis in the sinus mucosa, with increased non-Type 2 cytokines in the nasal lavage.Conclusions: S. aureus and P. aeruginosa are more potent inducers of neutrophilic inflammation than S. pneumoniae in mice. This model allows us to further study non-eosinophilic chronic rhinosinusitis pathophysiology in vivo.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"353-362"},"PeriodicalIF":4.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and feasibility of the endoscopic endonasal approach to anterior skull base tumour resections in young children. 幼儿前颅底肿瘤切除术采用内窥镜鼻内入路的安全性和可行性。

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.494

M Castellanos, D K Lerner, S A Hamimi, A D Workman, J E Douglas, M A Kohanski, P B Storm, J N Palmer, N D Adappa

引用次数: 0

Comparison of outcomes for Draf IIB vs Draf III in endoscopic frontal sinus surgery: a comprehensive systematic review and meta-analysis. 草案IIB与草案III在内镜额窦手术中的结果比较：一项全面的系统回顾和荟萃分析。

IF 4.8 2区医学

Rhinology Pub Date : 2025-06-01 DOI: 10.4193/Rhin24.507

Y Hirayama, M S Shahid, H A Finney, J Muzaffar, M S Haque, R Accorona, H Iftikhar

{"title":"Comparison of outcomes for Draf IIB vs Draf III in endoscopic frontal sinus surgery: a comprehensive systematic review and meta-analysis.","authors":"Y Hirayama, M S Shahid, H A Finney, J Muzaffar, M S Haque, R Accorona, H Iftikhar","doi":"10.4193/Rhin24.507","DOIUrl":"10.4193/Rhin24.507","url":null,"abstract":"Background: Understanding the factors associated with increased rates of restenosis following Draf procedures is crucial for developing targeted strategies to mitigate complications such as mucocele formation, reduce the need for revision surgeries, and improve long-term patient outcomes.Methodology: A systematic search was conducted using Embase, Medline, CINAHL, AMED, PubMed, and the Cochrane Database on January 17th, 2024. Research articles published in English language were included. Abstracts were independently screened by two reviewers, and data were extracted and assessed for quality in adherence to PRISMA guidelines. Meta- and sub-group analyses were conducted using the REML model and random-effects model to address high heterogenity and I2 values.Results: A total of 96 studies met the inclusion criteria. For the Draf IIB subgroup (15 studies, 239 sinuses), the restenosis rate was 7%, compared to 20% in the Draf III subgroup (40 studies, 1,910 sinuses). Revision surgery rates were 5% for Draf IIB versus 12% for Draf III. Adjuvant interventions, such as steroid-impregnated stents, were associated with improved outcomes, showing an ostium patency OR of 2.20.Conclusion: Draf IIB had superior outcomes compared to Draf III with respect to restenosis and revision surgery. The use of steroid-impregnated stents appears effective in reducing restenosis rates.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"258-285"},"PeriodicalIF":4.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0